Hubei Minkang Pharmaceutical LTD (HBMK) financial statements (2022 and earlier)
Company profile
| Business Address |
55 UBI AVE, #03-01 MINTWELL BUILDING, 408864 |
| State of Incorp. | NV |
| Fiscal Year End | December 31 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in thousands)
| 12/31/2013 | 12/31/2012 | |||
|---|---|---|---|---|
| ASSETS | ||||
| Current Assets | ||||
| Cash, cash equivalents, and short-term investments | 6,234 | 6,073 | ||
| Cash and cash equivalents | 6,234 | 6,073 | ||
| Receivables | 956 | 1,616 | ||
| Inventory, net of allowances, customer advances and progress billings | 3,985 | 3,221 | ||
| Inventory | 3,985 | 3,221 | ||
| Advances on inventory purchases | 576 | 484 | ||
| Deposits current assets | 589 | |||
| Prepaid expense and other current assets | ✕ | 39 | ||
| Other current assets | 1,575 | ✕ | ||
| Other undisclosed current assets | 685 | 1,765 | ||
| Total current assets: | 14,599 | 13,199 | ||
| Noncurrent Assets | ||||
| Property, plant and equipment | 4,740 | 4,848 | ||
| Other undisclosed noncurrent assets | 2,276 | 2,445 | ||
| Total noncurrent assets: | 7,016 | 7,293 | ||
| TOTAL ASSETS: | 21,615 | 20,491 | ||
| LIABILITIES AND EQUITY | ||||
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts payable and accrued liabilities | 2,278 | 3,404 | ||
| Accounts payable | 2,278 | 3,228 | ||
| Taxes payable | 176 | |||
| Debt | 3,272 | 3,170 | ||
| Other liabilities | 393 | 434 | ||
| Other undisclosed current liabilities | 4,245 | 2,530 | ||
| Total current liabilities: | 10,188 | 9,538 | ||
| Noncurrent Liabilities | ||||
| Total liabilities: | 10,188 | 9,538 | ||
| Stockholders' equity | ||||
| Stockholders' equity attributable to parent | 11,427 | 10,953 | ||
| Common stock | 52 | 52 | ||
| Additional paid in capital | 5,824 | 5,824 | ||
| Accumulated other comprehensive income | 1,718 | 1,371 | ||
| Retained earnings | 3,833 | 3,706 | ||
| Total stockholders' equity: | 11,427 | 10,953 | ||
| TOTAL LIABILITIES AND EQUITY: | 21,615 | 20,491 | ||
Income statement (P&L) ($ in thousands)
| 12/31/2013 | 12/31/2012 | ||
|---|---|---|---|
| Revenues | 14,743 | 13,919 | |
| Cost of revenue (Cost of Goods and Services Sold) | (8,314) | (7,163) | |
| Other undisclosed gross profit | (139) | ||
| Gross profit: | 6,289 | 6,756 | |
| Operating expenses | (6,555) | (5,898) | |
| Other undisclosed operating income | 308 | 167 | |
| Operating income: | 42 | 1,024 | |
| Nonoperating income (expense) | 32 | (70) | |
| Investment income, nonoperating | 31 | 22 | |
| Other nonoperating expense | (12) | (24) | |
| Interest and debt expense | (221) | (237) | |
| Other undisclosed income from continuing operations before equity method investments, income taxes | 221 | 237 | |
| Income from continuing operations before income taxes: | 73 | 955 | |
| Income tax benefit | 54 | 6 | |
| Net income available to common stockholders, diluted: | 127 | 961 | |
Comprehensive Income ($ in thousands)
| 12/31/2013 | 12/31/2012 | ||
|---|---|---|---|
| Net income: | 127 | 961 | |
| Comprehensive income: | 127 | 961 | |
| Other undisclosed comprehensive income, net of tax, attributable to parent | 347 | 68 | |
| Comprehensive income, net of tax, attributable to parent: | 474 | 1,030 | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.